The use of silicone rubber as a carrier for prolonged drug therapy

Folkman, Judah; Long, David M.

doi:10.1016/s0022-4804(64)80040-8

Cited by 324 publications

(108 citation statements)

References 1 publication

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…On discharge from the Navy, they gifted the patent "royalty-free" to the Population Council of the Rockefeller Foundation, who used the technology to develop an implantable sustained release contraceptive,Norplant. This technology is still used today for estradiol sustained release vaginal rings [27,31].…”

Section: Judah Folkman: the ''Father Of Angiogenesis''mentioning

confidence: 99%

Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond

Stephenson

Goddard

Al-Taan

et al. 2013

Journal of Cancer Research

View full text Add to dashboard Cite

Angiogenesis is the growth of new blood vessels in the body. Abnormal angiogenesis is recognised as a “common denominator” in many disease processes, and the development of angiogenesis inhibitors holds great hope in the ongoing battle against cancer. The field of angiogenesis has roots in the Hunterian era of the late eighteenth century but did not begin to blossom until the early 1970s when the then controversial findings and conclusions of Judah Folkman, the “father of angiogenesis,” were first published. There were only 65 publications with angiogenesis in the title in the 10 years after Folkman first proposed the idea of tumour angiogenesis, compared to over 9,000 publications from the year 2000 to 2010. In this review we will explore the voyage of discovery from the first observations of John Hunter in the eighteenth century, via the struggle faced by Folkman to prove the importance of angiogenesis, and finally how his determination has led to modern angiogenesis inhibitors being used in everyday clinical practice.

show abstract

Section: Judah Folkman: the ''Father Of Angiogenesis''mentioning

confidence: 99%

Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond

Stephenson

Goddard

Al-Taan

et al. 2013

Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…The development of man-made polymers for controlled release of therapeutic agents was triggered by discoveries made by Folkman and Long who demonstrated that hydrophobic dyes diffuse through a silicone tubing wall at a constant rate [101,102]. Since then, numerous polymeric materials and devices for drug delivery have been developed, including films, tablets, gels, microspheres and others [103,104].…”

Section: Nanocarriers For Cns Drug Deliverymentioning

confidence: 99%

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Kabanov

Gendelman

2007

Progress in Polymer Science

242

138

View full text Add to dashboard Cite

Neurodegenerative and infectious disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population's age. Alzheimer's disease alone currently affects 4.5 million Americans, and more than $100 billion is spent per year on medical and institutional care for affected people. Such numbers will double in the ensuing decades. Currently disease diagnosis for all disorders is made, in large measure, on clinical grounds as laboratory and neuroimaging tests confirm what is seen by more routine examination. Achieving early diagnosis would enable improved disease outcomes. Drugs, vaccines or regenerative proteins present "real" possibilities for positively affecting disease outcomes, but are limited in that their entry into the brain is commonly restricted across the blood-brain barrier. This review highlights how these obstacles can be overcome by polymer science and nanotechnology. Such approaches may improve diagnostic and therapeutic outcomes. New developments in polymer science coupled with cell-based delivery strategies support the notion that diseases that now have limited therapeutic options can show improved outcomes by advances in nanomedicine.

show abstract

“…Early studies using particulates as drug carriers were conducted in the 1960s, [1] and since then, there has been a plethora of carriers developed for drug delivery, including liposomes, micelles, dendrimers, and polymeric and inorganic particles. [2] The field of nanotechnology provides an avenue to engineer carriers with tailored composition, morphology, dimensions and surface properties, all of which can influence the biodistribution and pharmacokinetic profile of an encapsulated drug.…”

Section: Introductionmentioning

confidence: 99%

Particle Targeting in Complex Biological Media

Dai

Bertleff‐Zieschang

Braunger

et al. 2017

Adv Healthcare Materials

102

View full text Add to dashboard Cite

Over the past few decades, nanoengineered particles have gained increasing interest for applications in the biomedical realm, including diagnosis, imaging, and therapy. When functionalized with targeting ligands, these particles have the potential to interact with specific cells and tissues, and accumulate at desired target sites, reducing side effects and improve overall efficacy in applications such as vaccination and drug delivery. However, when targeted particles enter a complex biological environment, the adsorption of biomolecules and the formation of a surface coating (e.g., a protein corona) changes the properties of the carriers and can render their behavior unpredictable. For this reason, it is of importance to consider the potential challenges imposed by the biological environment at the early stages of particle design. This review describes parameters that affect the targeting ability of particulate drug carriers, with an emphasis on the effect of the protein corona. We highlight strategies for exploiting the protein corona to improve the targeting ability of particles. Finally, we provide suggestions for complementing current in vitro assays used for the evaluation of targeting and carrier efficacy with new and emerging techniques (e.g., 3D models and flow‐based technologies) to advance fundamental understanding in bio‐nano science and to accelerate the development of targeted particles for biomedical applications.

show abstract

The use of silicone rubber as a carrier for prolonged drug therapy

Cited by 324 publications

References 1 publication

Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond

Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond

Nanomedicine in the diagnosis and therapy of neurodegenerative disorders

Particle Targeting in Complex Biological Media

Contact Info

Product

Resources

About